Patheon to Showcase Softgel Technology at INTERPHEX
Patheon Inc. , the pharmaceutical services business owned by DPx Holdings, will showcase its softgel technologies at INTERPHEX in New York, N.Y., March 18-20, 2014.
Patheon’s Harry Gill, SVP, Quality and Continuous Improvement, will present, “Transforming Quality using Common Operational Excellence Tools,” on Wednesday, March 19 at 3:15 p.m. on Innovation Stage 2. Gill will explore how companies can utilize a holistic operational excellence program to drive improvements in one of the most basic quality KPI’s, Right First Time. He will review real case studies that show how using tools such as 5S, FMEA, Standard Work and Gemba can be applied to drive Quality Improvements.
In addition, many Patheon executives as well as technical and scientific experts will also attend INTERPHEX and will be available to discuss Patheon’s softgel technologies. Patheon is a world leader in softgel technologies, manufacturing and can customize alkali, acidic and non-animal gelatin shells for liquids, suspensions, semi-solids of any viscosity and solid fill materials. Representatives can be found at Booth #1438 and Booth #1211 for the duration of the conference. To schedule a meeting in advance, please email firstname.lastname@example.org .
INTERPHEX is the single source for complete biopharmaceutical and pharmaceutical manufacturing solutions to confidently process all dosage forms for life-enhancing drugs.
For more information on upcoming events, visit http://www.patheon.com/Knowledge-Library/Events.aspx .
Tel: (919) 226-3200
DPx is the privately held parent company of the Patheon, Banner Life Sciences, and DSM Fine Chemicals businesses. The company is a leading provider of CDMO services, pharmaceutical products and products for other industries. Founded in 2014 as a result of a deal between JLL Partners and Royal DSM, DPx has three core business units, comprised of Patheon Pharma Services, DSM Fine Chemicals and Banner Life Sciences. With global headquarters in Durham, N.C., DPx has a footprint of 24 locations across North America, Europe, Latin America and Australia with more than 8,000 employees. DPX offers customers unsurpassed quality, integrated offerings and value through these three core business units. For more information visit www.patheon.com/DPx .
Patheon is a leading provider of contract development and commercial manufacturing (CDMO) services to the global pharmaceutical industry for a full array of solid and sterile dosage forms. Patheon, a DPX business unit, encompasses the combined CMO capabilities and pharmaceutical product development services (PDS), as well as the Biosolutions and Biologics (BIO) business. For more information visit http://www.patheon.com .